Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.70 |
| ▸ | MC4R | P32245 | 1/20 | 0.68 |
| ▸ | HTR1A | P08908 | 1/20 | 0.67 |
| ▸ | DRD2 | P14416 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4627966 | 0.96 | SIGMAR1 (0.71) | SIGMAR1SLC6A3MC4RHTR1ADRD2 | |
| SCHEMBL2056159 | 0.93 | SLC6A3 (0.72) | SIGMAR1SLC6A3MC4RHTR1ADRD2 | |
| SCHEMBL6056974 | 0.91 | SLC6A3 (0.83) | SIGMAR1SLC6A3HTR1ADRD2ACHE | |
| SCHEMBL13150782 | 0.91 | SLC6A3 (0.83) | SIGMAR1SLC6A3HTR1ADRD2ACHE | |
| SCHEMBL14407778 | 0.91 | SLC6A3 (0.83) | SIGMAR1SLC6A3HTR1ADRD2ACHE | |
| SCHEMBL7264546 | 0.91 | SLC6A3 (0.83) | SIGMAR1SLC6A3HTR1ADRD2ACHE | |
| SCHEMBL21650852 | 0.88 | SIGMAR1 (0.61) | SIGMAR1SLC6A3MC4RHTR1ADRD2 | |
| SCHEMBL3593088 | 0.88 | SIGMAR1 (0.89) | SIGMAR1MC4R | |
| SCHEMBL2056151 | 0.86 | SIGMAR1 (1.00) | SIGMAR1MC4R | |
| SCHEMBL12668136 | 0.86 | SLC6A3 (0.68) | SIGMAR1SLC6A3HTR1ADRD2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | claimed |
| EP-2097419-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | Exelixis, Inc. (US) | 2009-09-09 | — | — | EP | claimed |
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | claimed |
| EP-1644338-A1 | 2, 4, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | Aponetics AG (CH) | 2006-04-12 | — | — | EP | claimed |
| WO-2004087679-A1 | 2, 4, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | APONETICS AG (CH) | 2004-10-14 | — | — | WO | claimed |
| CN-113200978-B | Isothia (selenium) azolone derivative and application thereof in anti-coronavirus drugs | 中国海洋大学 | 2022-09-16 | — | — | CN | disclosed |
| US-20220119396-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2022-04-21 | — | — | US | disclosed |
| EP-3145929-B1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS WHICH ARE JAK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-01-13 | — | — | EP | disclosed |
| EP-3322706-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-11-11 | — | — | EP | disclosed |
| WO-2020123847-A1 | ORGANIC COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2018136661-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-07-26 | — | — | WO | disclosed |
| US-10000450-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| WO-2007066784-A2 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | WO | disclosed |
| US-7220765-B2 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (SCRAS) (FR) | 2007-05-22 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119396-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, ROR1 | SIGMAR1 3258/4885SLC6A3 1914/4885MC4R 1194/4885 |
| US-10000450-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | SLC6A2, TPH1, SLC6A3 | SIGMAR1 65/4885SLC6A3 3/4885MC4R 352/4885 |
| US-20090247559-A1 | Benzofuropyrimidinones | F12, BRI3BP, BRD1 | SIGMAR1 647/4885SLC6A3 1276/4885MC4R 557/4885 |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, HTR3C | SIGMAR1 55/4885SLC6A3 10/4885MC4R 465/4885 |
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | SIGMAR1 136/4885SLC6A3 4136/4885MC4R 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.